Literature DB >> 20541272

The Groningen Radiotherapy-Induced Xerostomia questionnaire: development and validation of a new questionnaire.

Ivo Beetz1, Fred R Burlage, Henk P Bijl, Olga Hoegen-Chouvalova, Miranda E M C Christianen, Arjan Vissink, Bernard F A M van der Laan, Geertruida H de Bock, Johannes A Langendijk.   

Abstract

PURPOSE: The purpose of this study was to develop and validate a questionnaire (Groningen Radiotherapy-Induced Xerostomia (GRIX) questionnaire) that has the ability to distinguish between patient-rated xerostomia during day and night and can be used to evaluate the impact of emerging radiation delivery techniques aiming at prevention of xerostomia in more detail.
MATERIALS AND METHODS: All questions in the GRIX were generated from an exhaustive list of relevant questions according to xerostomia as reported in the literature and reported by patients and health care providers. Finally the GRIX was reduced from 56 questions to a 14-item questionnaire, with four subscales; xerostomia during day and night and sticky saliva during day and night. 315 patients filled out 2936 questionnaires and the GRIX was evaluated by calculating Crohnbach's α for all subscales. Criterion validity was evaluated to compare the GRIX with patient-rated xerostomia scored with the EORTC QLQ-HN35 and physician-rated xerostomia, test-retest analysis and responsiveness were also tested.
RESULTS: Crohnbach's α varied for all subscales between 0.88 and 0.94. The GRIX scored well for criterion-related validity on all subscales with high correlations with the EORTC QLQ-HN35 xerostomia and sticky saliva scale as well with physician-rated toxicity scoring. No significant differences were found between test and retest score and the GRIX showed good responsiveness with different time points for all subscales.
CONCLUSION: The GRIX is a validated questionnaire which can be used in future research focusing on patient-rated xerostomia and sticky saliva during day and night in relation with the impact of emerging radiation delivery techniques aiming at reduction of xerostomia.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20541272     DOI: 10.1016/j.radonc.2010.05.004

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  15 in total

Review 1.  Performance of the EORTC questionnaire for the assessment of quality of life in head and neck cancer patients EORTC QLQ-H&N35: a methodological review.

Authors:  Susanne Singer; Juan Ignacio Arraras; Wei-Chu Chie; Sheila E Fisher; Razvan Galalae; Eva Hammerlid; Ourania Nicolatou-Galitis; Claudia Schmalz; Irma Verdonck-de Leeuw; Eva Gamper; Judith Keszte; Dirk Hofmeister
Journal:  Qual Life Res       Date:  2012-11-28       Impact factor: 4.147

Review 2.  Treatment of late sequelae after radiotherapy for head and neck cancer.

Authors:  Primož Strojan; Katherine A Hutcheson; Avraham Eisbruch; Jonathan J Beitler; Johannes A Langendijk; Anne W M Lee; June Corry; William M Mendenhall; Robert Smee; Alessandra Rinaldo; Alfio Ferlito
Journal:  Cancer Treat Rev       Date:  2017-07-18       Impact factor: 12.111

3.  Radiotherapy-induced xerostomia, pre-clinical promise of LMS-611.

Authors:  Claire Paterson; B Caldwell; S Porteous; A McLean; C M Messow; M Thomson
Journal:  Support Care Cancer       Date:  2015-07-05       Impact factor: 3.603

4.  Assessment of radiation-induced xerostomia: validation of the Italian version of the xerostomia questionnaire in head and neck cancer patients.

Authors:  Federica Pellegrino; Elena Groff; Luca Bastiani; Bruno Fattori; Guido Sotti
Journal:  Support Care Cancer       Date:  2014-09-19       Impact factor: 3.603

5.  N-Acetylcysteine Rinse for Thick Secretion and Mucositis of Head and Neck Chemoradiotherapy (Alliance MC13C2): A Double-Blind Randomized Clinical Trial.

Authors:  Terence T Sio; Miran J Blanchard; Paul J Novotny; Samir H Patel; Jean-Claude M Rwigema; Levi D Pederson; Lisa A McGee; Mauricio E Gamez; Grant R Seeger; James A Martenson; Yvonne Grover; Michelle A Neben Wittich; Yolanda I Garces; Robert L Foote; Robert C Miller; Michele Y Halyard
Journal:  Mayo Clin Proc       Date:  2019-08-09       Impact factor: 7.616

6.  TIGAR overexpression diminishes radiosensitivity of parotid gland fibroblast cells and inhibits IR-induced cell autophagy.

Authors:  Guomei Tai; Haowen Zhang; Jie Du; Guojian Chen; Jianfeng Huang; Jiahua Yu; Jing Cai; Fenju Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 7.  Cost-effectiveness landscape analysis of treatments addressing xerostomia in patients receiving head and neck radiation therapy.

Authors:  Laura S Sasportas; Drew N Hosford; Maria A Sodini; Dale J Waters; Elizabeth A Zambricki; Joëlle K Barral; Edward E Graves; Todd J Brinton; Paul G Yock; Quynh-Thu Le; Davud Sirjani
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2013-05-03

Review 8.  Using PROMs to guide patients and practitioners through the head and neck cancer journey.

Authors:  Simon N Rogers; Brittany Barber
Journal:  Patient Relat Outcome Meas       Date:  2017-11-08

9.  Uniform FDG-PET guided GRAdient Dose prEscription to reduce late Radiation Toxicity (UPGRADE-RT): study protocol for a randomized clinical trial with dose reduction to the elective neck in head and neck squamous cell carcinoma.

Authors:  Sven van den Bosch; Tim Dijkema; Martina C Kunze-Busch; Chris H J Terhaard; Cornelis P J Raaijmakers; Patricia A H Doornaert; Frank J P Hoebers; Marije R Vergeer; Bas Kreike; Oda B Wijers; Wim J G Oyen; Johannes H A M Kaanders
Journal:  BMC Cancer       Date:  2017-03-21       Impact factor: 4.430

10.  Pharmacokinetics of Sublingually Delivered Fentanyl in Head and Neck Cancer Patients Treated with Curatively Aimed Chemo or Bioradiotherapy.

Authors:  Evelien J M Kuip; Wendy H Oldenmenger; Esther Oomen-de Hoop; Gerda M Verduijn; Martine F Thijs-Visser; Peter de Bruijn; Esther van Meerten; Stijn L W Koolen; Ron H J Mathijssen; Carin C D van der Rijt
Journal:  Cancers (Basel)       Date:  2018-11-15       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.